Alderley Analytical appoints new Associate Director of Business Development
We’re delighted to announce that Justin Wildgoose has been appointed to our team as Associate Director, Business Development. Justin joins Alderley Analytical from Q2 Solutions where he was responsible for business development in the bioanalysis and ADME division.
Justin brings not just a wealth of business development and commercial expertise to the role, but as an ex-Study Director, a sound foundation in bioanalysis. In positions at ICON and others, he specialised in discovery, pre-clinical, PI and PII small molecule drug development programmes.
Commenting on the appointment, Alderley Analytical CEO Liz Thomas said, “We have ambitious plans for growth, following on from a very successful year, so Justin joins us at the perfect time. I know he’s looking forward to meeting our clients and sharing our expertise and customer-focussed ethos with the industry.”